West Synchrony™ S1 Prefillable Syringe System Commercially Available at Pharmapack

West Pharmaceutical Services (NYSE: WST) announced the global commercial availability of the West Synchrony™ S1 prefillable syringe (PFS) system at Pharmapack 2026 in Paris on January 20, 2026.

Rhea-AI Summary

West Pharmaceutical Services (NYSE: WST) announced the global commercial availability of the West Synchrony™ S1 prefillable syringe (PFS) system at Pharmapack 2026 in Paris on January 20, 2026. The system offers 1 ml long and 2.25 ml staked needle options for biologics, plus 1 ml standard staked needle and Luer lock options for vaccines, with rigid or soft needle shields and integrated tip caps. The platform includes West NovaPure® and FluroTec™ barrier film plungers. West will present learning labs and a product gallery at Pharmapack on January 21–22, 2026 to highlight integrated solutions and combination-product support.

Argus Jan 20 session

-3.58% close to close Open Argus

Details

News Market Reaction – WST

On Jan 20, the day this news came out, WST closed 3.58% below the previous close.

Data tracked by StockTitan Argus for the Jan 20 session.

Key Figures

Syringe size option: 1 ml long Syringe size option: 2.25 ml Quarterly dividend: $0.22 per share +5 more

Syringe size option

1 ml long

West Synchrony S1 PFS system configuration for biologics

Syringe size option

2.25 ml

West Synchrony S1 staked needle option for biologics

Quarterly dividend

$0.22 per share

Regular quarterly dividend declared payable February 4, 2026

Q3 2025 net sales

$804.6 million

Quarterly net sales reported in 10-Q, up from $746.9 million

Q3 2025 diluted EPS

$1.92

Diluted EPS for Q3 2025, up from $1.85

Operating cash flow

$503.7 million

Operating cash flow for first nine months of 2025

Cash and equivalents

$628.5 million

Cash and cash equivalents at September 30, 2025

High-Value Products mix

48%

HVP components as share of Q3 2025 sales

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Asset sale / facility

   24h Move

   -0.9%

   AbbVie agreed to acquire Tempe device facility and related IP from West.

2. Jan 12

   Product rights sale

   24h Move

   -0.9%

   West to sell SmartDose 3.5mL manufacturing and supply rights to AbbVie for cash.

3. Dec 12

   Investor conference

   24h Move

   -1.8%

   Announcement of presentation at the J.P. Morgan Healthcare Conference with webcast.

4. Dec 10

   Dividend declaration

   24h Move

   +0.3%

   Board declared a regular quarterly dividend of $0.22 per share with set dates.

5. Oct 27

   Product launch

   24h Move

   -3.5%

   Launch of West Synchrony Prefillable Syringe System with availability in Jan 2026.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

prefillable syringe, staked needle, luer lock, combination products

4 terms

prefillable syringe technical

"This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system."

A prefillable syringe is a single-use injection device designed to be filled and sealed with a specific drug dose ahead of use, so a nurse or patient can administer medication quickly without measuring. Think of it like a ready-to-pour travel bottle instead of scooping from a big container. For investors, prefillable syringes can increase a therapy’s safety, ease of use and market appeal, and they influence manufacturing costs, supply chain choices and regulatory risk.

staked needle technical

"1 ml long and 2.25 ml staked needle options for biologics and 1 ml standard staked needle and Luer lock options"

A staked needle is a hypodermic needle permanently fixed into the hub of a syringe or medical device during manufacturing, like a tree branch welded into a handle so it won’t wobble or fall out. For investors, that construction affects a product’s reliability, sterility and manufacturing cost, which in turn influence regulatory clearance, production scale-up and competitive positioning in markets for disposable injections and drug-delivery devices.

luer lock technical

"1 ml standard staked needle and Luer lock options for vaccines."

A luer lock is a small, standardized threaded connector used on syringes, needles and tubing so medical parts twist together and stay sealed, like a screw cap on a bottle. For investors it matters because this simple design affects product compatibility, safety, regulatory approval, manufacturing cost and liability risk—factors that influence market acceptance and the commercial value of medical devices and supplies.

combination products technical

"growing demand for combination products alongside the movement of care from hospital to home"

Combination products are medical offerings that merge two or more types of treatments or delivery systems—such as a drug with a medical device or a biological therapy with an implant—into a single product. For investors, they matter because combining parts can raise development cost and regulatory scrutiny but also create stronger competitive advantages, higher pricing power, and stickier customer adoption; think of them like a smartphone that bundles hardware and software into one sold product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Showcasing Leadership in Drug Delivery Solutions and Approaches to Combination Products

EXTON, Pa., Jan. 20, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced participation at Pharmapack 2026 in Paris, France to showcase its leadership and expertise on industry challenges and trends in packaging and containment. This event marks the global commercial availability of West Synchrony™ S1 prefillable syringe (PFS) system.

West Synchrony S1 PFS system provides a broad product portfolio including 1 ml long and 2.25 ml staked needle options for biologics and 1 ml standard staked needle and Luer lock options for vaccines. Staked needle system options come with either a rigid or soft needle shield and Luer lock system options will have an integrated tip cap. The system also includes high performance West NovaPure® and FluroTec™ barrier film plungers.

"As a market leader, West closely monitors shifts in the global drug pipeline by emerging companies, particularly the growing demand for combination products alongside the movement of care from hospital to home, both of which introduce new complexity into regulatory and development processes," Stacey Vaughan, Vice President, Marketing and Portfolio Management at West. "This surge of innovation across the industry further highlights why now is the right time to introduce West Synchrony S1 prefillable syringe system."

In addition, West will highlight its industry expertise through learning labs and a product gallery:

• Stop Piecing It Together—Get an Integrated Verified Prefillable Syringe System from One Source- Wednesday, January 21, 11:30 a.m.- 12:00 p.m. CET
  • Presented by Bettine Boltres Ph.D., Director of Scientific Affairs
• Product Gallery- West Synchrony S1 PFS System- Wednesday, January 21, 3:25-3:30 p.m. CET
  • Presented by Andy Polywacz, President of Integrated Systems
• Flexible Assembly and Packaging Approach for Steering Combination Products Through Clinical Trials- Thursday, January 22, 10:10- 10:40 a.m. CET
  • Presented by Richard Kieran, Director of Business Development          

For more information about West Synchrony S1 PFS system, click here.

For more information about Pharmapack, click here.

Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as "standard," "streamline," "accelerate," "secures," "reliable," "meets," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations.  Specifically, there is no certainty that West's introduction of the Synchrony PFS system will achieve any particular result.  These forward-looking statements involve a number of risks and uncertainties. Various factors could cause the actual results to differ materially from those expressed in, or underlying, these forward-looking statements, such as customers' changing inventory requirements and manufacturing plans; customer decisions to move forward with new products and product categories; average profitability, or mix, of the products offered for sale; dependence on third party suppliers and partners; interruptions or weaknesses in the supply chain; increased raw material costs; fluctuations in currency exchange; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2024. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West   
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of lifesaving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites including 25 manufacturing facilities worldwide, West helps support our customers by delivering over 41 billion components and devices each year.  

Headquartered in Exton, Pennsylvania, West in its fiscal year 2024 generated $2.89 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. 

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/west-synchrony-s1-prefillable-syringe-system-commercially-available-at-pharmapack-302664737.html

SOURCE West Pharmaceutical Services, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the West Synchrony S1 prefillable syringe system that WST announced on January 20, 2026?

The West Synchrony S1 PFS system is a commercially available syringe platform offering 1 ml long and 2.25 ml staked needle options for biologics and 1 ml standard staked needle and Luer lock options for vaccines, plus NovaPure and FluroTec plungers.

Where and when did West (WST) announce commercial availability of the Synchrony S1 system?

West announced global commercial availability at Pharmapack 2026 in Paris, dated January 20, 2026, with product sessions on January 21–22, 2026.

Which syringe configurations does the West Synchrony S1 system include for vaccines and biologics?

For biologics: 1 ml long and 2.25 ml staked needle options; for vaccines: 1 ml standard staked needle and Luer lock options with integrated tip caps.

What protective features are offered with West Synchrony S1 staked needle and Luer lock options?

Staked needle options come with either a rigid or soft needle shield; Luer lock options include an integrated tip cap.

How is West showcasing the Synchrony S1 system at Pharmapack and who are the presenters?

West will host a learning lab and product gallery at Pharmapack on January 21–22, 2026, with presentations by Bettine Boltres Ph.D., Andy Polywacz, and Richard Kieran.